Preclinical studies in animal models have demonstrated that survodutide effectively activates both GLP-1R and GCGR, resulting in reduced body weight, slower gastric emptying, decreased energy intake, increased energy expenditure, and improved glucose tolerance [86]
Understanding the Market Shake-Up and What It Means for Private Practices In a move that sent ripples across the pharmaceutical and medical community, Novo Nordisk has announced that CEO Lars Fruergaard Jrgensen will step down after 34 years, citing market challenges and a 53% drop in share price
(And Why Fillers Aren't the Answer) The "Ozempic Body": Deflation and the Abdominal Apron Timing is Everything: When is it Safe to Have Surgery
Recent analyses presented at the National Lipid Associations 2025 Scientific Sessions highlighted cardiovascular, renal, and metabolic gains from GLP1s that appear partly independent of the amount of weight loss
What GLP-1 Actually Is GLP-1 stands for Glucagon Like Peptide 1